These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16509467)

  • 1. Acute pancreatitis following antilymphocyte globulin therapy in a renal transplant recipient.
    Lee WC; Wu MJ; Cheng CH; Chen CH; Wen MC; Chen HC; Shu KH
    Clin Nephrol; 2006 Feb; 65(2):144-6. PubMed ID: 16509467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute pancreatitis complicating OKT3 administration for resistant cardiac rejection.
    Scheinin S; Radovancevic B; Frazier OH
    Transplant Proc; 1993 Jun; 25(3):2368-9. PubMed ID: 8516933
    [No Abstract]   [Full Text] [Related]  

  • 4. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
    Boratyńska M; Szepietowski T; Szewczyk Z; Szydłowski Z
    Arch Immunol Ther Exp (Warsz); 1992; 40(2):163-8. PubMed ID: 1299176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
    Alamartine E; Bellakoul R; Berthoux F
    Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 7. The risk of infection following OKT3 and antilymphocyte globulin treatment for renal transplant rejection: results of a single center prospectively randomized trial.
    Hesse UJ; Wienand P; Baldamus C; Pollok M; Pichlmaier H
    Transpl Int; 1992; 5 Suppl 1():S440-3. PubMed ID: 14621840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antilymphocyte serum, cyclosporine and corticoids, versus OKT3, cyclosporine, and corticoids in kidney transplantation].
    Grino JM; Castelao AM; Seron D; Gonzalez C; Gil-Vernet S; Andres E; Bover J; Mestre M; Alsina J
    Presse Med; 1991 Nov; 20(40):2039-42. PubMed ID: 1837121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
    Cecka JM; Gjertson D; Terasaki PI
    Transplant Proc; 1993 Feb; 25(1 Pt 1):548-9. PubMed ID: 8438408
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment with poly- and monoclonal antilymphocyte antibodies: assessment of efficacy and safety in transplantation.
    Claesson K; Tufveson G; Wahlberg J
    Transplant Proc; 1992 Feb; 24(1):314. PubMed ID: 1539293
    [No Abstract]   [Full Text] [Related]  

  • 11. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression.
    McAlister V; Grant D; Roy A; Yilmaz Z; Ghent C; Wall W
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1400-1. PubMed ID: 8442154
    [No Abstract]   [Full Text] [Related]  

  • 12. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
    Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS
    Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Histopathological findings and clinical effects for acute rejections].
    Takahara S; Toki K; Ichimaru N; Kokado Y; Wang DJ; Okuyama A; Miyamoto M; Kameoka H; Inoue T; Nanba Y; Kyakuno M; Nakamura T; Kyo M
    Hinyokika Kiyo; 1998 May; 44(5):365-8. PubMed ID: 9656111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK; Kim YS; Kim MS; Kim SI; Park K
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylaxis with a short course of OKT3 in renal transplantation: comparative analysis with recipients treated either with prophylactic ATG or with CyA.
    Lloveras J; Puig JM; Oliveras A; Orfila A; Comerma I; Aubia J; Masramón J
    Transplant Proc; 1992 Feb; 24(1):43-4. PubMed ID: 1539335
    [No Abstract]   [Full Text] [Related]  

  • 16. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytokine nephropathy during antilymphocyte therapy.
    Batiuk TD; Bennett WM; Norman DJ
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):27-30. PubMed ID: 8465418
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 19. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
    Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
    Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.